Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Clara Allayous et al.|European Journal of Cancer|2018Cited by 38
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control studyLéo Plaçais, Célèste Lebbé, Délphine Legoupil et al.|Annals of the Rheumatic Diseases|2022Cited by 34
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆Y. Di Filippo, Henri Montaudié, Stéphane Dalle et al.|Annals of Oncology|2020Cited by 30
Quality‐of‐life assessment in French patients with metastatic melanoma in real lifeM. Kandel, Isabelle Borget, Stéphane Dalle et al.|Cancer|2019Cited by 14
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalA. Vallet, Bastien Oriano, Laurent Mortier et al.|JAMA Dermatology|2019Cited by 10